5–15 mg, ip, qd No learn more difference   Less

tumour viability [127] Walker carcinosarkoma 256 Rats Iscador M, 0.005–0.5 mg, im, qd No difference   Metastases: AZD1480 nmr no difference [128] Autochthonous             Methylnitrosurea-induced Rats (Sprague Dawley) Iscador M c. Arg., sc, 0,2 ml/day, 50 mg/week * 6 weeks 75% -16%   [124] sc: subcutaneous; im: intramuscular; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week; qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span All experiments did have control groups, but these were only mentioned if necessary for results I Part of a screening programme for substances with anticancer activity (1,000 plant extracts from 107 plant species) II Relating to volume of ascites; effects greatest with therapy started on day -7 Table 9 Animal Studies of VAE Compounds in Breast or Gynaecological Cancer (transplanted human or murine tumours) Tumour, site Animal VAE Tumour growth T/C (%) Survival Other outcomes Reference Human breast tumour Breast Mice rML 0,3 ng/kg – 3 μg/kg, ip, qd * 5 * 2–4 w No effect     [129] Murine breast tumour in mice C3L5, adenocarcinoma; sc Mice (C3H7HeJ) ML I,

1 ng/kg, sc, q3d, selleck compound day 7–19 160   27.6 lung-metastases [130]     IL-2, twice 6 × 104 IU/mouse, ip q8h 2 * qd * 5 43   2.3 lung-metastases       Combination of ML 1 & IL-2 37   2.3 lung-metastases       Control     7.5 lung-metastases   ECa, ip

Mice (ICR) ML I, 80 ng, ip, day 1   70% died after 50 days   [131]     A-chain of ML I, 100 μg, ip, day 1   80% died after 57 days         B-chain of ML I, 10 μg, ip, day 1   80% died after 58 days         Control   100% died after 20 days     ECa, sc Mice (BALB/c) VAE 5 kDa peptides, 2 μg, it, day 7     Severe necrosis, infiltration of lymphocytes and macrophages [122] ECa, ip Mice (CD-1) Vester’ Proteins, ip, 0.1 or 1 Venetoclax or 10 μ/kg, qd * 10   ILS: 0, 33, and -33%I   [132] ECa Mice Polysaccharide („Viscumsäure“), ip, qd * 6 Slight effect     [133] Adenocarcinoma EO 771 Mice Polysaccharide („Viscumsäure“), ip, qd * 6 Moderate effect     [133] Murine breast tumour in rats Walker Carcinosarcoma Rats Polysaccharide („Viscumsäure“), ip, qd * 6 Moderate effect     [133] Other gynaecological tumour Ovary, SoTü 3, ip Mice (SCID) rML 30 ng/kg, ip, qd * 5 * 12   35% mice alive at day 84 40% tumour-free mice at day 84 [134]     rML 150 ng/kg, ip, qd * 5 * 12   10% mice alive at day 84 10% tumour-free mice at day 84       rML 500 ng/kg, ip, qd * 5 * 12   75% mice alive at day 84 65% tumour-free mice at day 84       Control   15 mice alive at day 84 10% tumour-free mice at day 84   Uterusepithelioma T-8 Guérin Rats Polysaccharide (“”Viscumsäure”"), ip, qd * 6 Moderate effect     [133] All experiments did have control groups, but these were only mentioned if necessary for results.